[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49386-49387]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23175]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Computer-Aided 
Diagnosis of Prostate Cancer in Multi-Parametric MRI

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute and Clinical Center, institutes 
of the National Institutes of Health, Department of Health and Human 
Services, are contemplating the grant of an Exclusive Patent License to 
practice the inventions embodied in the U.S. Patents and Patent 
Applications listed in the SUPPLEMENTARY INFORMATION section of this 
notice to ScanMed, LLC located in Omaha, NE.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before November 9, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be

[[Page 49387]]

directed to: Tedd Fenn, Senior Technology Transfer Manager, NCI 
Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 
9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-
9702, Telephone: (240)-276-5530; Facsimile: (240)-276-5504, Email: 
[email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    United States Provisional Patent Application No. 62/462,256 filed 
February 22, 2017 ``Computer-Aided Diagnosis of Prostate Cancer in 
Multi-parametric MRI''
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: ``Class II or III computer-assisted diagnostics 
systems for use with Magnetic Resonance Imaging, of the anatomy of the 
prostate.''
    The subject technology is an automated computer assisted diagnostic 
system for processing and visualizing prostate lesions on MRI. The 
system uses specialized algorithms (an ensemble of multiple random 
decision trees, Random Forest) that is trained against: (1) Hand drawn 
contours, (2) recorded biopsy results, and (3) normal cases from 
randomly sampled patient images weighted for lesion size. The system 
produces a probability map of potential cancerous lesions in 
multiparametric MRI.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice within the 15 days of this 
notice, will be treated as objections to the grant of the contemplated 
Exclusive Patent License Agreement. Comments and objections submitted 
to this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 19, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2017-23175 Filed 10-24-17; 8:45 am]
 BILLING CODE 4140-01-P